Effect of Passive Immunization on the Progression of Alzheimer's Disease: LY2062430 Versus Placebo

Trial Profile

Effect of Passive Immunization on the Progression of Alzheimer's Disease: LY2062430 Versus Placebo

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Jul 2017

At a glance

  • Drugs Solanezumab (Primary)
  • Indications Alzheimer's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms EXPEDITION-2
  • Sponsors Eli Lilly
  • Most Recent Events

    • 20 Jul 2017 Results of PK/PD model development and evaluation using patient data from NCT00905372, NCT00904683, NCT01900665 trials presented at the Alzheimer's Association International Conference 2017
    • 20 Jul 2017 Results presenting treatment-emergent adverse event (AE) findings from the 18-month double-blind periods of EXPEDITION3 and from the pooled data from EXPEDITION and EXPEDITION2 (subjects with mild AD dementia at baseline in either study) and EXPEDITION3 presented at the Alzheimer's Association International Conference 2017
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top